Company intelligence / Profile preview

Molecule.one

Warsaw, Mazowieckie, Polandmolecule.one ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Molecule.one has developed an AI-powered platform that automates chemical retrosynthesis and reaction prediction. Their high-throughput chemistry lab runs up to 60,000 reactions monthly to generate data for model training. The technology accelerates the design of novel synthetic routes for pharmaceuticals across multiple therapeutic areas but does not itself have clinical results as it does not develop drugs directly.

Therapeutic areas: OncologyCardiovascularInfectious Diseases
Modalities: Small molecule (focus on synthesis and drug discovery for small molecules)
Industry: Drug Discovery Services

Partnerships

Charles River Laboratories (collaboration on M1 RetroScore tool for drug discovery)

Beyond the preview

Go deeper on Molecule.one.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecule.one.

Explore the full profile